ADC THERAPEUTICS SA's ticker is ADCT and the CUSIP is H0036K147. A total of 61 filers reported holding ADC THERAPEUTICS SA in Q2 2022. The put-call ratio across all filers is 0.74 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,375,936 | -61.6% | 1,533,931 | -8.0% | 0.00% | – |
| Q2 2023 | $3,583,431 | +11.7% | 1,666,712 | +1.3% | 0.00% | – |
| Q1 2023 | $3,207,376 | -47.9% | 1,644,808 | +2.5% | 0.00% | -100.0% |
| Q4 2022 | $6,161,764 | +18572.0% | 1,604,626 | +23287.6% | 0.00% | – |
| Q3 2022 | $33,000 | -34.0% | 6,861 | +8.2% | 0.00% | – |
| Q2 2022 | $50,000 | -55.4% | 6,342 | -16.7% | 0.00% | – |
| Q1 2022 | $112,000 | -94.5% | 7,609 | -92.5% | 0.00% | – |
| Q4 2021 | $2,038,000 | +805.8% | 100,877 | +1121.9% | 0.00% | – |
| Q3 2021 | $225,000 | -6.2% | 8,256 | -16.5% | 0.00% | – |
| Q2 2021 | $240,000 | -29.2% | 9,886 | -28.8% | 0.00% | – |
| Q1 2021 | $339,000 | +340.3% | 13,879 | +474.2% | 0.00% | – |
| Q4 2020 | $77,000 | -40.3% | 2,417 | -38.3% | 0.00% | – |
| Q3 2020 | $129,000 | -21.3% | 3,917 | +11.6% | 0.00% | – |
| Q2 2020 | $164,000 | – | 3,510 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vantage Consulting Group Inc | 1,680,149 | $33,939,000 | 9.12% |
| Redmile Group, LLC | 7,451,029 | $150,511,000 | 3.42% |
| Grosvenor Holdings, L.L.C. | 1,517,212 | $30,648,000 | 3.17% |
| Indie Asset Partners, LLC | 96,582 | $1,951,000 | 1.42% |
| MPM BioImpact LLC | 337,396 | $6,815,000 | 1.24% |
| Eventide Asset Management | 1,975,000 | $39,895,000 | 0.51% |
| HHLR ADVISORS, LTD. | 500,000 | $10,100,000 | 0.16% |
| Virtus ETF Advisers LLC | 19,193 | $388,000 | 0.15% |
| CNA FINANCIAL CORP | 15,245 | $308,000 | 0.08% |
| Employees Retirement System of Texas | 278,000 | $5,616,000 | 0.06% |